Idacio: Uses, Dosage & Side Effects
A biosimilar adalimumab TNF-alpha inhibitor for autoimmune and inflammatory conditions including rheumatoid arthritis, psoriasis, and Crohn's disease
Idacio (adalimumab) is a prescription biologic medicine classified as a tumor necrosis factor alpha (TNF-alpha) inhibitor. It is a biosimilar to the reference product Humira and contains the same active substance, adalimumab, a fully human recombinant monoclonal antibody. Idacio is approved for the treatment of multiple autoimmune and inflammatory conditions in adults and children, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. It works by binding to and neutralizing TNF-alpha, a key pro-inflammatory cytokine that drives the pathological immune response in these conditions. Idacio is administered as a subcutaneous injection, typically 40 mg every other week, and can be self-injected at home after proper training.
Quick Facts: Idacio
Key Takeaways
- Idacio is an EMA-approved biosimilar of Humira (adalimumab), containing the same active substance at the same concentration (40 mg/0.8 mL), with demonstrated equivalent efficacy, safety, and immunogenicity through rigorous clinical studies.
- It is indicated for a wide range of autoimmune conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and certain pediatric populations.
- Tuberculosis screening is mandatory before starting Idacio, as TNF-alpha inhibitors increase the risk of reactivating latent tuberculosis and other serious infections including invasive fungal infections and opportunistic pathogens.
- The standard adult dosage is 40 mg by subcutaneous injection every other week, though some conditions may require an initial loading dose; the injection can be self-administered at home after proper training from a healthcare professional.
- Live vaccines must not be administered during Idacio treatment, and infants exposed to adalimumab in utero should not receive live vaccines for at least 5 months after the mother's last injection during pregnancy.
What Is Idacio and What Is It Used For?
Idacio contains the active substance adalimumab, a fully human recombinant immunoglobulin G1 (IgG1) monoclonal antibody produced using Chinese hamster ovary (CHO) cell culture and recombinant DNA technology. Adalimumab was originally developed and marketed as Humira, which became one of the most widely prescribed biologic medicines in the world. Idacio is a biosimilar to Humira, meaning it has been rigorously tested and shown to be highly similar to the reference product with no clinically meaningful differences in quality, safety, or efficacy. The European Medicines Agency (EMA) approved Idacio in 2019 following comprehensive analytical, non-clinical, and clinical comparisons with the reference product.
As a TNF-alpha inhibitor, adalimumab targets a specific protein called tumor necrosis factor alpha (TNF-alpha) that plays a central role in the inflammatory cascade underlying many autoimmune diseases. TNF-alpha is a pro-inflammatory cytokine produced primarily by activated macrophages, T lymphocytes, and other immune cells. In healthy individuals, TNF-alpha serves important functions in immune defense against infections and in wound healing. However, in autoimmune conditions, the immune system produces excessive amounts of TNF-alpha, leading to chronic inflammation that damages the body's own tissues. This overproduction of TNF-alpha drives joint destruction in rheumatoid arthritis, intestinal inflammation in inflammatory bowel disease, and skin cell proliferation in psoriasis, among other pathological processes.
Adalimumab works by binding specifically to TNF-alpha with high affinity and neutralizing its biological activity. It blocks the interaction between TNF-alpha and its cell surface receptors (p55/TNFR1 and p75/TNFR2), thereby preventing the downstream inflammatory signaling cascade. Additionally, adalimumab can lyse cells that express surface-bound TNF-alpha through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. This dual mechanism of action—neutralizing soluble TNF-alpha and targeting membrane-bound TNF-alpha on immune cells—contributes to the comprehensive anti-inflammatory effects observed clinically. By reducing TNF-alpha signaling, adalimumab decreases the levels of other inflammatory mediators including interleukin-6 (IL-6), C-reactive protein (CRP), matrix metalloproteinases (which cause tissue destruction), and adhesion molecules (which recruit inflammatory cells to disease sites).
Idacio is approved for the treatment of the following conditions in adults:
- Rheumatoid arthritis (RA): For moderate to severe active RA in combination with methotrexate, or as monotherapy when methotrexate is inappropriate. Adalimumab reduces signs and symptoms, inhibits the progression of structural joint damage, and improves physical function.
- Psoriatic arthritis (PsA): For active and progressive psoriatic arthritis in adults who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs).
- Ankylosing spondylitis (AS): For severe active ankylosing spondylitis in adults who have had an inadequate response to conventional therapy.
- Axial spondyloarthritis without radiographic evidence: For severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI.
- Crohn's disease: For moderately to severely active Crohn's disease in adults who have not responded adequately to conventional therapy, including corticosteroids and/or immunosuppressants, or who are intolerant of or have contraindications to such therapies.
- Ulcerative colitis: For moderately to severely active ulcerative colitis in adults who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine.
- Plaque psoriasis: For moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy.
- Hidradenitis suppurativa (HS): For active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents (from 12 years of age) with an inadequate response to conventional systemic therapy.
- Non-infectious uveitis: For non-infectious intermediate, posterior, and panuveitis in adults who have had an inadequate response to corticosteroids, or as a corticosteroid-sparing agent.
In pediatric patients, Idacio is approved for juvenile idiopathic arthritis (from 2 years of age), pediatric Crohn's disease (from 6 years of age), pediatric plaque psoriasis (from 4 years of age), and pediatric non-infectious uveitis (from 2 years of age). The availability of biosimilar adalimumab products like Idacio has significantly improved access to this important biologic therapy, offering a more affordable alternative to the originator product while maintaining the same high standards of quality, safety, and efficacy demanded by regulatory authorities.
A biosimilar is a biologic medicine that is highly similar to an already approved reference biologic (in this case, Humira). Unlike generic medicines for small-molecule drugs, biosimilars are produced using living organisms and cannot be exact copies due to the inherent variability of biological manufacturing. Instead, biosimilars undergo extensive comparability studies to demonstrate that they have no clinically meaningful differences from the reference product in terms of quality, safety, and efficacy. The EMA, FDA, and WHO have established rigorous regulatory pathways for biosimilar approval. Switching between a reference biologic and its biosimilar is considered safe and effective based on robust evidence from multiple clinical studies.
What Should You Know Before Taking Idacio?
Contraindications
Idacio must not be used in patients with known hypersensitivity to adalimumab or to any of the excipients in the formulation (sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, mannitol, polysorbate 80, and water for injections). Additionally, Idacio is contraindicated in patients with active tuberculosis or other severe infections such as sepsis, and in patients with moderate to severe heart failure (NYHA class III/IV). These contraindications are critical because TNF-alpha inhibition fundamentally alters the immune response, and using adalimumab in the presence of active infections or severe cardiac compromise can lead to life-threatening complications.
Active tuberculosis is an absolute contraindication because TNF-alpha plays an essential role in the formation and maintenance of granulomas, which are the body's primary defense mechanism for containing Mycobacterium tuberculosis. Blocking TNF-alpha in a patient with active TB can cause rapid dissemination of the infection, potentially leading to fatal miliary tuberculosis or tuberculous meningitis. Similarly, other severe infections can worsen rapidly when the TNF-alpha-mediated immune response is suppressed.
Warnings and Precautions
TNF-alpha inhibitors including adalimumab increase the risk of serious infections that may lead to hospitalization or death. These include bacterial sepsis, tuberculosis (including reactivation of latent TB), invasive fungal infections (histoplasmosis, coccidioidomycosis, aspergillosis), and opportunistic infections. If a serious infection develops, stop Idacio and initiate appropriate antimicrobial therapy immediately. Patients should be closely monitored during and after treatment.
Before initiating Idacio therapy, your healthcare provider should conduct a thorough assessment including the following:
- Tuberculosis screening: All patients must be evaluated for both active and latent tuberculosis before starting Idacio. This includes a detailed medical history, a tuberculin skin test (TST) or interferon-gamma release assay (IGRA), and a chest X-ray. If latent TB is diagnosed, appropriate anti-tuberculosis prophylaxis must be started before initiating Idacio. Patients should continue to be monitored for signs and symptoms of TB during and after treatment, even if the initial screening was negative, as false-negative results can occur, particularly in immunosuppressed patients.
- Hepatitis B screening: Reactivation of hepatitis B virus (HBV) has been reported in patients who are chronic HBV carriers and are treated with TNF-alpha inhibitors. Some cases have been fatal. Patients should be tested for HBV infection before starting Idacio. For patients who test positive for HBV surface antigen, consultation with a hepatologist is recommended. If Idacio is used in HBV carriers, they should be closely monitored for signs and symptoms of active HBV infection throughout treatment and for several months after stopping treatment.
- Malignancy risk: An increased risk of lymphoma and other malignancies, some fatal, has been reported in children and adolescents treated with TNF-alpha inhibitors. In adult patients with rheumatoid arthritis and other chronic inflammatory diseases, TNF inhibitor therapy may be associated with a modest increase in the risk of lymphoma. Patients with a history of malignancy or who develop malignancy during treatment should be carefully assessed. Caution is advised when considering TNF inhibitor therapy in patients with a history of malignancy or when continuing treatment in patients who develop a new malignancy.
- Heart failure: Worsening and new-onset congestive heart failure has been reported with TNF-alpha inhibitors. In clinical trials of another TNF inhibitor, worsening heart failure and increased mortality were observed. Idacio should be used with caution in patients with mild heart failure (NYHA class I/II), and patients should be closely monitored. Treatment should be discontinued in patients who develop new or worsening heart failure symptoms.
- Demyelinating disorders: Rare cases of new-onset or exacerbation of demyelinating disorders, including multiple sclerosis and Guillain-Barré syndrome, have been reported with TNF-alpha inhibitors. Caution is advised when considering adalimumab in patients with pre-existing or recently developing demyelinating disorders of the central or peripheral nervous system.
- Surgical procedures: Limited safety data exist regarding surgical procedures in patients treated with adalimumab. The long half-life of adalimumab (approximately 14 days) should be considered when planning surgery. Patients undergoing surgical procedures should be carefully monitored for infections.
Pregnancy and Breastfeeding
Adalimumab should only be used during pregnancy if clearly necessary. As a monoclonal IgG1 antibody, adalimumab crosses the placental barrier, with transfer increasing throughout gestation and reaching the highest levels during the third trimester. Infants born to mothers treated with adalimumab during pregnancy may have an increased risk of infection due to in utero exposure. It is critically important that infants exposed to adalimumab in utero do not receive live vaccines (such as BCG, rotavirus, or measles-mumps-rubella) for at least 5 months after the mother's last adalimumab injection during pregnancy. Administration of live vaccines to these infants could result in disseminated infection.
Women of childbearing potential should use adequate contraception during treatment with Idacio and for at least 5 months after the last dose. If you discover that you are pregnant while on Idacio, contact your doctor immediately. The decision to continue or discontinue treatment should weigh the benefits of disease control for the mother against the potential risks to the fetus.
Adalimumab has been detected in very low concentrations in breast milk (approximately 0.1–1% of maternal serum levels). Because IgG antibodies are excreted in human milk and adalimumab is poorly absorbed from the gastrointestinal tract, the risk to the breastfed infant is considered low. However, a risk cannot be entirely excluded. The decision to breastfeed during Idacio treatment should be made in consultation with your healthcare provider, weighing the benefits of breastfeeding for the infant against the benefits of treatment for the mother.
Children and Adolescents
Idacio is approved for use in certain pediatric populations. Juvenile idiopathic arthritis can be treated from 2 years of age, pediatric Crohn's disease from 6 years of age, pediatric plaque psoriasis from 4 years of age, and pediatric non-infectious uveitis from 2 years of age. Dosing in children is typically based on body weight. The safety and efficacy of adalimumab in children below the age limits specified for each indication have not been established. There is a concern about the potential risk of malignancies in children and adolescents treated with TNF-alpha inhibitors, and parents and caregivers should be informed about this risk and the importance of regular monitoring.
How Does Idacio Interact with Other Drugs?
Drug interactions with adalimumab are primarily pharmacodynamic rather than pharmacokinetic in nature. Because adalimumab is a monoclonal antibody, it is catabolized through proteolysis rather than metabolized by cytochrome P450 enzymes, meaning traditional drug-drug interactions involving hepatic enzyme inhibition or induction are not a concern. However, the immunosuppressive mechanism of action of adalimumab creates clinically important interactions with other medications that affect the immune system.
Methotrexate (MTX) is the most common concomitant medication used with adalimumab, particularly in rheumatoid arthritis. Studies have shown that methotrexate reduces the formation of anti-drug antibodies (immunogenicity) against adalimumab, which can improve the long-term efficacy of treatment. The combination of adalimumab and methotrexate is considered the standard of care for moderate to severe rheumatoid arthritis based on landmark trials demonstrating superior outcomes compared with either agent alone. Other conventional DMARDs such as sulfasalazine, hydroxychloroquine, and leflunomide can also be used concomitantly with adalimumab.
| Interacting Drug | Type | Effect | Recommendation |
|---|---|---|---|
| Methotrexate | Beneficial | Reduces anti-drug antibody formation; improved efficacy in RA | Recommended combination for RA; standard of care |
| Abatacept (Orencia) | Major | Increased risk of serious infections without additional benefit | Do not combine; avoid concurrent use |
| Anakinra (Kineret) | Major | Significantly increased risk of serious infections and neutropenia | Do not combine; avoid concurrent use |
| Other biologic DMARDs | Major | Additive immunosuppression; increased infection risk | Do not combine with other TNF inhibitors or biologics |
| Live vaccines | Major | Risk of disseminated infection from live vaccine organisms | Contraindicated during treatment; update vaccines before starting |
| Azathioprine / 6-MP | Moderate | Additive immunosuppression; rare risk of hepatosplenic T-cell lymphoma | Use with caution; monitor closely, especially in young males |
| Corticosteroids | Moderate | Additive immunosuppression; increased infection risk | Taper corticosteroids when possible; monitor for infections |
| CYP450 substrates (e.g., warfarin, theophylline) | Minor | TNF-alpha suppression may normalize CYP450 levels, altering drug metabolism | Monitor levels when initiating or discontinuing adalimumab |
Live and Inactivated Vaccines
Patients on Idacio must not receive live vaccines. The immunosuppressive effect of adalimumab can allow live vaccine organisms to replicate in an uncontrolled manner, potentially causing serious or fatal infections. Examples of live vaccines that are contraindicated include BCG (tuberculosis), measles-mumps-rubella (MMR), varicella (chickenpox), rotavirus, yellow fever, and live attenuated influenza (nasal spray). Inactivated vaccines (such as inactivated influenza, pneumococcal, hepatitis B, and tetanus-diphtheria) can be administered during adalimumab treatment, although the immune response may be somewhat reduced.
It is strongly recommended that patients update all age-appropriate vaccinations before starting Idacio therapy. This includes pneumococcal vaccination, annual influenza vaccination, and hepatitis B vaccination if not previously immunized. Planning vaccinations in advance allows patients to receive any necessary live vaccines before commencing immunosuppressive therapy.
What Is the Correct Dosage of Idacio?
Idacio treatment should be initiated and supervised by a specialist physician experienced in the diagnosis and treatment of the conditions for which it is indicated. Patients may self-inject Idacio after receiving proper training from their healthcare professional on injection technique, aseptic precautions, and proper disposal of used syringes. The injection should be administered subcutaneously into the abdomen (at least 5 cm from the navel) or the front of the thigh. Injection sites should be rotated, and injections should not be given into areas where the skin is tender, bruised, red, or hard.
| Condition | Loading Dose | Maintenance Dose | Notes |
|---|---|---|---|
| Rheumatoid Arthritis | None required | 40 mg every other week | May increase to 40 mg weekly if inadequate response on MTX; can be used as monotherapy |
| Psoriatic Arthritis | None required | 40 mg every other week | Monotherapy or with MTX/other DMARDs |
| Ankylosing Spondylitis | None required | 40 mg every other week | Also for axial spondyloarthritis without radiographic evidence |
| Crohn's Disease (adults) | 160 mg at week 0, 80 mg at week 2 | 40 mg every other week | May increase to 40 mg weekly if response decreases |
| Ulcerative Colitis | 160 mg at week 0, 80 mg at week 2 | 40 mg every other week | May increase to 40 mg weekly if response decreases |
| Plaque Psoriasis | 80 mg at week 0 | 40 mg every other week from week 1 | Reassess if no response within 16 weeks |
| Hidradenitis Suppurativa | 160 mg at week 0, 80 mg at week 2 | 40 mg weekly from week 4 | If response insufficient, may add antibiotics |
| Non-infectious Uveitis | 80 mg at week 0 | 40 mg every other week from week 1 | May use concomitant corticosteroids; taper as appropriate |
Adults
The standard adult dose of Idacio across most indications is 40 mg administered subcutaneously every other week (every 14 days). For rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no loading dose is required, and treatment begins at the maintenance dose of 40 mg every other week. In patients with rheumatoid arthritis who are not taking methotrexate concurrently, some patients may benefit from increasing the dose frequency to 40 mg every week, particularly if they experience an inadequate response at the standard dose.
For gastrointestinal conditions (Crohn's disease and ulcerative colitis), a higher loading dose is necessary to achieve therapeutic drug levels more rapidly. Treatment begins with 160 mg at week 0 (administered as four injections in one day or two injections per day for two consecutive days), followed by 80 mg at week 2 (two injections in one day), and then the maintenance dose of 40 mg every other week starting at week 4. If a patient's response decreases during maintenance treatment, the dose frequency may be increased to 40 mg every week.
Plaque psoriasis and non-infectious uveitis require a loading dose of 80 mg at week 0, followed by the maintenance dose of 40 mg every other week from week 1. For hidradenitis suppurativa, the induction regimen is 160 mg at week 0, 80 mg at week 2, and then 40 mg every week (not every other week) as maintenance from week 4 onward. If inadequate response is observed after 12 weeks, the benefit of continued treatment should be carefully reconsidered.
Pediatric Dosing
Pediatric dosing of adalimumab is typically based on body weight. For juvenile idiopathic arthritis (from 2 years of age), children weighing 10 to less than 30 kg receive 20 mg every other week, while children weighing 30 kg or more receive 40 mg every other week. For pediatric Crohn's disease (from 6 years of age), dosing also follows weight-based protocols with appropriate loading doses. The prescribing physician will determine the appropriate dose and schedule based on the child's weight, age, and specific condition.
Elderly Patients
No dose adjustment is required for elderly patients. However, due to the higher incidence of infections in the elderly population, caution should be exercised when treating elderly patients with Idacio. Close monitoring for signs and symptoms of infection is particularly important in this group. The benefit-risk balance should be carefully considered before initiating treatment in elderly patients, taking into account comorbidities and the potential for increased susceptibility to serious infections.
Missed Dose
If you miss a dose of Idacio, inject the missed dose as soon as you remember. Then take your next dose at the originally scheduled time. Do not inject two doses at the same time to make up for a missed dose. If you are uncertain about when to take your next dose, contact your healthcare provider or pharmacist for guidance. Setting reminders on your phone or marking injection dates on a calendar can help ensure doses are not missed, as consistent dosing is important for maintaining optimal drug levels and disease control.
Overdose
No dose-limiting toxicity has been observed in clinical trials with adalimumab. The maximum dose evaluated has been multiple intravenous doses of 10 mg/kg, which is substantially higher than the recommended therapeutic dose. In the event of an overdose, the patient should be monitored for any signs or symptoms of adverse reactions or effects, and appropriate symptomatic treatment should be initiated immediately. There is no specific antidote for adalimumab overdose. Due to the long half-life of the molecule (approximately 14 days), close monitoring may be required for an extended period following an overdose.
What Are the Side Effects of Idacio?
Like all medicines, Idacio can cause side effects, although not everybody experiences them. The most frequently reported adverse reactions with adalimumab are infections and injection site reactions. Serious adverse reactions include serious infections, malignancies, and hypersensitivity reactions. The overall safety profile of adalimumab is well-characterized from extensive clinical trial data and decades of post-marketing experience with the reference product Humira, which has been used by millions of patients worldwide. Idacio has been shown through comparability studies to have a consistent safety profile with the reference product.
The following side effects have been observed with adalimumab treatment, organized by frequency according to the MedDRA convention:
Very Common
Affects more than 1 in 10 people
- Injection site reactions (pain, redness, swelling, itching, bruising)
- Upper respiratory tract infections (cold, sinusitis, pharyngitis)
- Headache
- Musculoskeletal pain (back pain, muscle pain)
- Elevated liver enzymes
Common
Affects 1 in 10 to 1 in 100 people
- Lower respiratory tract infections (bronchitis, pneumonia)
- Urinary tract infections
- Herpes simplex, herpes zoster (shingles)
- Nausea, abdominal pain, diarrhea
- Rash, itching (pruritus)
- Fatigue
- Dizziness
- Elevated blood lipids (cholesterol, triglycerides)
- Leukopenia (low white blood cell count)
- Autoantibody formation (ANA positive)
- Hair loss (alopecia)
- Hypertension (high blood pressure)
- Mouth ulcers
- Pyrexia (fever)
Uncommon
Affects 1 in 100 to 1 in 1,000 people
- Serious infections (sepsis, opportunistic infections)
- Tuberculosis (including miliary and extrapulmonary TB)
- Skin cancer (basal cell carcinoma, squamous cell carcinoma)
- Lymphoma
- Pancytopenia, thrombocytopenia
- Severe allergic reactions (anaphylaxis)
- Lupus-like syndrome
- Demyelinating disorders (optic neuritis, Guillain-Barré syndrome)
- Interstitial lung disease
- Heart failure (new onset or worsening)
- Hepatitis, liver failure
- Psoriasis (new onset or worsening, including pustular forms)
- Benign tumors, cysts
Rare
Affects less than 1 in 1,000 people
- Hepatosplenic T-cell lymphoma (primarily in young males on combination therapy)
- Merkel cell carcinoma
- Aplastic anemia
- Stevens-Johnson syndrome, erythema multiforme
- Vasculitis (cutaneous)
- Sarcoidosis
- Reactivation of hepatitis B
Contact your doctor or seek emergency care immediately if you develop: signs of serious infection (persistent fever, night sweats, weight loss, cough, or difficulty breathing); symptoms of allergic reaction (rash, swelling of face or throat, difficulty breathing); signs of blood disorders (persistent fever, bruising, bleeding, or paleness); unexplained neurological symptoms (numbness, tingling, vision changes, or weakness in limbs); or new or worsening symptoms of heart failure (shortness of breath, swelling of ankles).
It is important to understand that while the list of potential side effects may appear extensive, most patients tolerate adalimumab well. Injection site reactions are the most commonly experienced side effect and typically diminish with continued use. The risk of serious adverse events must be weighed against the significant benefits that adalimumab provides in controlling inflammatory diseases that can cause substantial disability and reduced quality of life if left inadequately treated. Your healthcare provider will monitor you regularly with blood tests and clinical assessments to detect any potential complications early.
How Should You Store Idacio?
Proper storage of Idacio is essential to maintain the effectiveness and safety of the medication. As a biologic medicine containing a protein (adalimumab), Idacio is sensitive to temperature extremes and must be handled carefully to preserve its integrity. The following storage guidelines should be followed:
- Refrigerated storage: Store Idacio in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. If the product has been accidentally frozen, it should not be used and must be discarded, even if it has been thawed, as freezing can damage the protein structure of the antibody and alter its efficacy and safety profile.
- Light protection: Keep Idacio in the original outer carton to protect it from light. Exposure to light can degrade the active protein, reducing the medication's effectiveness over time.
- Room temperature storage: If necessary, a single Idacio pre-filled syringe may be removed from the refrigerator and stored at room temperature (up to 25°C / 77°F) for a maximum period of 14 days. The syringe should be protected from light during this period. After 14 days at room temperature, the syringe must be used or discarded; it cannot be returned to the refrigerator for later use.
- Before injection: Allow the pre-filled syringe to reach room temperature naturally for approximately 15–30 minutes before injection. Do not heat the syringe using hot water, a microwave, or any other heat source. Injecting cold solution may cause increased discomfort at the injection site.
- Visual inspection: Before use, visually inspect the solution. It should be clear to slightly opalescent, colorless to light yellow. Do not use if the solution is cloudy, discolored, or contains visible particles.
Keep Idacio out of the sight and reach of children. Do not use after the expiry date stated on the carton and syringe label. Used syringes should be disposed of in an approved sharps container according to local regulations. Do not dispose of used syringes in household waste.
What Does Idacio Contain?
Idacio is a sterile, preservative-free solution for subcutaneous injection supplied in pre-filled syringes. Each pre-filled syringe contains 0.8 mL of solution providing 40 mg of adalimumab. The concentration is therefore 50 mg/mL. Adalimumab, the active ingredient, is a recombinant human IgG1 monoclonal antibody with a molecular weight of approximately 148 kilodaltons (kDa). It is produced using Chinese hamster ovary (CHO) cell culture and purified through a series of chromatographic and viral inactivation/removal steps that ensure product purity and safety.
The inactive ingredients (excipients) in Idacio include:
- Sodium dihydrogen phosphate dihydrate: Buffer component that helps maintain the pH of the solution at an optimal level for protein stability (approximately pH 5.8).
- Disodium phosphate dihydrate: Co-buffer that works with sodium dihydrogen phosphate to maintain solution pH within the desired range.
- Mannitol: A sugar alcohol that serves as a tonicity agent, ensuring the injection solution has an osmolality similar to body fluids, which reduces pain and irritation at the injection site.
- Polysorbate 80: A non-ionic surfactant that prevents protein aggregation and adsorption to container surfaces, helping to maintain the stability and uniformity of the adalimumab molecules in solution.
- Water for injections: The solvent that comprises the bulk of the solution volume.
Idacio does not contain preservatives, latex (in the needle cap), or any animal-derived ingredients other than the CHO cell-produced antibody itself. The solution contains less than 1 mmol (23 mg) of sodium per dose, making it essentially sodium-free for patients on sodium-restricted diets. Patients with known allergies to any of the excipients listed above should not use Idacio and should discuss alternative treatment options with their healthcare provider.
Frequently Asked Questions About Idacio
Idacio is a biosimilar of Humira, meaning it contains the same active substance (adalimumab) and has been shown through extensive analytical, non-clinical, and clinical testing to be highly similar to Humira with no clinically meaningful differences in efficacy, safety, or immunogenicity. The main difference is that Idacio is manufactured by Fresenius Kabi rather than AbbVie (the manufacturer of Humira). As a biosimilar, Idacio is typically available at a lower cost than the originator product, improving patient access to this important biologic therapy. Clinical data and regulatory assessments from the EMA confirm that switching between Humira and Idacio is safe and effective.
The onset of effect with Idacio varies depending on the condition being treated. In rheumatoid arthritis, some patients may notice improvement within 1–2 weeks, although the full effect typically develops over 12 weeks of treatment. For psoriasis, significant skin clearance is usually observed within 12–16 weeks. In Crohn's disease and ulcerative colitis, clinical remission may be achieved within 4–8 weeks, particularly with the induction dosing regimen. Your doctor will typically assess your response after 12–16 weeks and decide whether to continue treatment based on your clinical improvement.
There is no specific interaction between adalimumab and alcohol. However, excessive alcohol consumption can increase the risk of liver damage, particularly when adalimumab is used in combination with methotrexate (which is itself hepatotoxic). Alcohol also impairs immune function, which could compound the immunosuppressive effects of Idacio and increase infection risk. Moderate alcohol consumption is generally considered acceptable, but you should discuss your alcohol intake with your healthcare provider, especially if you are taking concurrent medications that affect the liver.
Yes, you can travel with Idacio, but you need to plan ahead to maintain the cold chain. Use an insulated travel bag with ice packs (not dry ice) to keep the medication between 2–8°C during transit. For air travel, carry Idacio in your hand luggage (not checked baggage) to avoid extreme temperatures in the cargo hold. Bring a letter from your healthcare provider confirming you need to carry injectable medication and sharps. If refrigeration is unavailable at your destination, a single pre-filled syringe can be stored at room temperature (up to 25°C) for up to 14 days.
If you develop signs or symptoms of infection while taking Idacio (such as fever, persistent cough, flu-like symptoms, fatigue, or wound infections), contact your healthcare provider promptly. Mild infections (such as a common cold) can usually be managed while continuing treatment, but your doctor may advise temporarily stopping Idacio if the infection is more serious. Do not administer your next dose without consulting your doctor if you have an active infection. Serious infections may require hospitalization, intravenous antibiotics, and discontinuation of Idacio until the infection is fully resolved.
Idacio is typically used as a long-term treatment. Many autoimmune conditions are chronic, and adalimumab is often continued for years as long as it remains effective and well-tolerated. Long-term safety data for adalimumab spans over 20 years, and many patients have been treated continuously for a decade or more. Your doctor will regularly reassess the benefit-risk balance of continued treatment. In some cases, if your disease is in sustained remission, your doctor may consider reducing the dose frequency or attempting a treatment holiday, but this decision should always be made in consultation with your specialist.
References
- European Medicines Agency. Idacio (adalimumab) – Summary of Product Characteristics. EMA/CHMP, 2025. Available at: ema.europa.eu
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924–939. doi:10.1002/acr.24596
- Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. doi:10.1136/ard-2022-223356
- Joint Formulary Committee. British National Formulary (BNF). Adalimumab. London: BMJ Group and Pharmaceutical Press. Updated 2025.
- World Health Organization. WHO Expert Committee on Biological Standardization – Guidelines on evaluation of biosimilars. WHO Technical Report Series No. 1004. Geneva: WHO, 2017.
- Kay J, Schoels MM, Dörner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165–174. doi:10.1136/annrheumdis-2017-211937
- Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi:10.1016/j.jaad.2018.11.057
- Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4–22. doi:10.1093/ecco-jcc/jjz180
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a multidisciplinary group of licensed healthcare professionals with expertise in rheumatology, clinical pharmacology, gastroenterology, and dermatology.
Medical Content Team
Licensed physicians specializing in rheumatology and clinical immunology with expertise in biologic therapies and autoimmune disease management.
Pharmacology Reviewers
Clinical pharmacologists and pharmacists with expertise in biologic medicines, biosimilars, drug interactions, and adverse effect monitoring.
Evidence Review Board
Specialists in evidence-based medicine who verify all clinical claims against current peer-reviewed literature and international treatment guidelines.
Accessibility & Quality
Digital health specialists ensuring WCAG 2.2 AAA compliance and medical content clarity for patients of all health literacy levels.
All content follows the GRADE evidence framework and is reviewed according to guidelines from the ACR, EULAR, EMA, FDA, BNF, and WHO. iMedic receives no commercial funding and has no conflicts of interest with pharmaceutical companies.